5U01AG061356-05 |
2022 |
$2728790 |
Multi-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targets |
3U01AG061356-04S2 |
2022 |
$155483 |
A shared foundation for single genetic investigations of immune responses |
3U01AG061356-04S1 |
2022 |
$405000 |
Integration of immune cell subtypes across diseases & tissue |
3U01AG061356-03S1 |
2021 |
$416605 |
Multi-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targets |
5U01AG061356-04 |
2021 |
$2242312 |
Multi-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targets |
5U01AG061356-03 |
2020 |
$3049965 |
Multi-omic network-directed proteoform discovery; dissection and functional validation to prioritize novel AD therapeutic targets |
3U01AG061356-02S2 |
2020 |
$1215000 |
Multi-omic network-directed proteoform discovery; dissection and functional validation to prioritize novel AD therapeutic targets |
3U01AG061356-02S1 |
2020 |
$181181 |
Multi-omic network-directed proteoform discovery; dissection and functional validation to prioritize novel AD therapeutic targets |
5U01AG061356-02 |
2019 |
$1648575 |
Multi-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targets |
1U01AG061356-01 |
2018 |
$1668072 |
Multi-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targets |